腾盛博药生物科技有限公司（股票名称：腾盛博药-B，股票代码：02137）于2026年7月7日发布了截至2026年6月30日的股份变动月报表。
报告期内，公司注册股本未发生变化，仍为1,200,000,000股，票面价值每股0.000005美元，合计注册股本为6,000美元。上月底公司已发行股份（不含库存股）为721,806,998股，库存股12,723,500股，合计734,530,498股。
本月公司通过股权激励及股份奖励计划共计新增发行46,559股。其中，2023年购股权计划行使期权1,500股，首次公开发售后股份奖励计划新增45,059股。本月末公司已发行股份（不含库存股）增至721,853,557股，库存股仍为12,723,500股，总股本变动至734,577,057股。报告期内未出现股份回购或注销情况。
公司在公告中表示，已根据相关法律法规及香港联合交易所有限公司《上市规则》履行全部必要程序，并确认截至报告期末公司已维持足够的公众持股量。该公告由公司联席公司秘书李安康博士签署。
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.